System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Mathieu Kerneis is an expert in Cardiology at Pitié-Salpêtrière Hospital (France). As of October 2026, ScienceLeadR ranks Mathieu Kerneis in the top 1% of experts worldwide for Myocarditis, Cardiomyopathies and Myocardial Ischemia. Mathieu Kerneis has authored 270 publications, the most recent in 2026, and is an investigator in 22 clinical trials, 6 of them ongoing. SLR score: 1,238 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Mathieu Kerneis Pitié-Salpêtrière Hospital France
1 238 ScienceLeadR Reputation 1238

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Public Health - Critical Care - Biostatistics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2010 - 2026
Source: PubMed

Assistance Publique - Hôpitaux de Paris

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 270

Citations

Citations: 8 783 1st author: 19 Last author: 7 Unique author: 1

Main journals

Eur Heart J 52
Arch Cardiovasc Dis 15
J Am Coll Cardiol 15
Circulation 14
JACC Cardiovasc Interv 10

Best Journals

Eur Heart J 18
N Engl J Med 5
Circulation 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.
PMID 42669300 — myocardial infarction, heart failure, heart, therapeutics		Lancet Top journal20261
Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.
PMID 42747817 — glucagon-like peptide 1, quality of life, safety, cardiovascular diseases, frailty, semaglutide		JAMA Cardiol20260
Prognostic impact of pericardial effusion in patients with acute myocarditis.
PMID 42670209 — pericardial effusion, cardiovascular diseases, phenotype, myocarditis, echocardiography		Eur Heart J Acute Cardiovasc Care20261
LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial.
PMID 42666092 — cholesterol, ldl, myocardial infarction, percutaneous coronary intervention, cholesterol, odds ratio, therapeutics		JAMA Top journal20261
Inflammation in coronary syndromes in clinical practice: a clinical consensus statement of the Association for Acute Cardiovascular Care of the European Society of Cardiology, the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, the European Society of Cardiology Council on Basic Cardiovascular Science, and the European Society of Cardiology Council for Cardiology Practice.
PMID 42536391 — cytokines, cardiovascular diseases, cardiology, air, obesity, therapeutics, tissues		Eur Heart J Acute Cardiovasc Care20261

Clinical Studies 22

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Director: 1

By phase:

Phase 3 11
Phase 4 5
Phase 2 3
N/A 2
Phase 2/Phase 3 1

By status:

Completed 13
Recruiting 5
Unknown 2
Active not recruiting 1
Terminated 1

By type:

Interventional 21
Observational 1

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 5
multicentric5to9 1
multicentricup10 10

Main Topics

Cohort/Consortium Investigators 5

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of Transition Regimens to KPL 387 Monotherapy in Participants with Well Controlled Recurrent Pericarditis
2025-523234-66-00 — safety, pericarditis, therapeutics		Phase 2Recruiting2026
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and or Chronic Kidney Disease (ATTAIN Outcomes)
2025-523123-22-00 — kidney diseases, incidence, cardiovascular diseases, kidney, atherosclerosis		Phase 3Recruiting2026
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and or Chronic Kidney Disease (ATTAIN Outcomes)
NCT07241390 — kidney diseases, heart diseases, stroke, incidence, heart, cardiovascular diseases, kidney, atherosclerosis, renal insufficiency, renal insufficiency, chronic		Phase 3Recruiting2025
Colchicine Versus Placebo in Acute Myocarditis Patients
NCT05855746 — enzyme inhibitors, angiotensin-converting enzyme inhibitors, colchicine, heart failure, pharmaceutical preparations, heart, arrhythmias, cardiac, peptidyl-dipeptidase a, contraindications, cardiology, angiotensins, myocarditis, enzymes, nausea, diuretics, drug tapering, therapeutics, diarrhea, random allocation		Phase 3Recruiting2024
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
NCT04951856 — injections, myocardial infarction, st elevation myocardial infarction, hydroxymethylglutaryl-coa reductase inhibitors, non-st elevated myocardial infarction, random allocation, injections, subcutaneous		Phase 4Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS